FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:627-629 August 27, 1998 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Cave, H. C. PubMed Citation

Measurement is the backbone of science, and the science of hematology is no exception. For many years, the number of normal or abnormal cells in the blood and bone marrow has been determined by counting cells visually or electronically and identifying them by microscopical inspection. In biologic terms, these traditional methods have very limited sensitivity, but recently developed, more sensitive techniques are providing new information of theoretical and practical value. The report by Cavé et al. in this issue of the Journal ¹ indicates the value of a molecular method of quantifying leukemic cells in patients with acute lymphoblastic leukemia (ALL) . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., Hughes, T. (2007). BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Clin. Cancer Res. 13: 7080-7085 [Abstract] [Full Text]  
• Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., Radich, J. P., the International Randomised Study of Interferon v, (2003). Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. NEJM 349: 1423-1432 [Abstract] [Full Text]  
• Lin, F., Drummond, M., O'Brien, S., Cervantes, F., Goldman, J., Kaeda, J. (2003). Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood 102: 1143-1143 [Full Text]  
• Hochhaus, A., Reiter, A., Reichert, S. S.{b.}e. A., Emig, M., Kaeda, J., Schultheis, B., Berger, U., Shepherd, P. C. A., Allan, N. C., Hehlmann, R., Goldman, J. M., Cross, N. C. P. (2000). Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95: 62-66 [Abstract] [Full Text]